Demographic and clinical characteristics of 334 patients with confirmed or suspected COVID-19 and rheumatic diseases
| Variables | n | % |
| Female | 275 | 81.4 |
| Age, median (IQR) | 45 (31–57) | |
| Professions that deal with the public | 126 | 37.3 |
| Active at work | 186 | 55.0 |
| Retired/ work leave due rheumatic disease* | 230 | 69.0 |
| Social isolation | 159 | 47.0 |
| Close contact with a confirmed case of COVID-19 | 159 | 47.0 |
| Comorbidities | ||
| Hypertension | 121 | 35.8 |
| Obesity | 53 | 15.7 |
| Diabetes | 39 | 11.5 |
| Hypothyroidism | 20 | 5.9 |
| Lung disease | 32 | 9.4 |
| Heart disease | 25 | 7.4 |
| Dyslipidaemia | 22 | 6.5 |
| Fibromyalgia | 12 | 3.6 |
| Kidney disease | 21 | 6.2 |
| Smoking | 15 | 4.4 |
| Alcoholism | 8 | 2.4 |
| Depression | 7 | 2.1 |
| Rheumatic diseases diagnostic | ||
| Systemic lupus erythematosus | 110 | 32.9 |
| Rheumatoid arthritis | 95 | 28.4 |
| Axial Spondyloarthritis | 45 | 13.5 |
| Systemic sclerosis | 23 | 6.9 |
| Psoriatic arthritis | 23 | 6.9 |
| Vasculitis | 10 | 3.3 |
| Others | 28 | 8.3 |
| Rheumatic disease treatment | ||
| Hydroxychloroquine | 118 | 34.9 |
| Oral corticosteroids | 116 | 34.3 |
| Methotrexate | 68 | 20.1 |
| Azathioprine | 42 | 12.4 |
| Leflunomide | 23 | 11.8 |
| Mycophenolate mofetil | 21 | 6.2 |
| TNFi | 75 | 22.2 |
| Non-TNFi | 41 | 12.1 |
| Rituximab | 13 | 3.8 |
| Anti-IL-17 | 12 | 3.6 |
| Tocilizumab | 9 | 2.7 |
| Belimumab | 3 | 0.9 |
| Abatacept | 3 | 0.9 |
| Anti-IL12-23 | 1 | 0.3 |
| JAK-inhibitors | 12 | 3.6 |
| Cyclophosphamide (pulse therapy) | 10 | 3.0 |
| Methylprednisolone (pulse therapy) | 8 | 2.4 |
| COVID-19 symptoms | ||
| Cough | 195 | 56.7 |
| Shortness of breath | 160 | 46.5 |
| Headache | 200 | 58.0 |
| Asthenia | 165 | 47.9 |
| Fever | 176 | 51.2 |
| Anosmia | 153 | 44.4 |
| Rhinorrhea | 111 | 32.2 |
| Joint pain | 72 | 21.0 |
| Myalgia | 140 | 40.8 |
| Dysgeusia | 146 | 42.3 |
| COVID-19 lab confirmation | 255 | 76.0 |
| RT-PCR | 175 | 51.8 |
| SARS-CoV-2 Serology (IgM or IgG) | 98 | 29.3 |
| Unknown | 30 | 8.9 |
| Emergency care | 160 | 48.0 |
| Hospitalised | 110 | 33.0 |
| Discharge alive | 66 | 19.8 |
| Intensive unit care | 50 | 15.0 |
| Mechanical ventilation | 35 | 10.5 |
| Death | 28 | 8.4 |
*Among 148 inactive at work
GC, glucocorticoids; IL-17, interleukin 17; JAK, Janus kinase; TNFi, tumour necrosis factor inhibitor.